Chugai Pharmaceutical Deal History & Licensing Activity
Chugai Pharmaceutical is a large pharma headquartered in Japan. Over the past three years, Chugai Pharmaceutical has been involved in 4 licensing and acquisition transactions, with a primary focus on Other (2 deals). The company currently has 30 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
1
Active Trials
30
Top Modality
Other
Focus Area
Solid Tumors
Chugai Pharmaceutical Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Chugai Pharmaceutical in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Renalys renal disease program | Renalys Pharma | Other | Unknown | acquisition | Jun 2026 |
Chugai Pharmaceutical Pipeline Focus
Therapeutic areas and modalities where Chugai Pharmaceutical is most active based on deal history and clinical trial data.
Therapeutic Areas
Chugai Pharmaceutical Strategic Signals
Key indicators of Chugai Pharmaceutical's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Chugai Pharmaceutical Clinical Pipeline
Chugai Pharmaceutical has 30 active clinical trials across 3 development phases.
10
Phase 1
3
Phase 2
17
Phase 3
See How Your Asset Matches Chugai Pharmaceutical's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Mab Benchmarks
Upfront, milestone, and royalty benchmarks for mab deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Chugai Pharmaceutical Licensing & Deal Activity
Chugai Pharmaceutical is a large pharma company based in Japan that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Chugai Pharmaceutical ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Chugai Pharmaceutical include Solid Tumors (9 deals and trials), Autoimmune (5 deals and trials), Oncology (3 deals and trials), and Mega Deals (2 deals and trials). In terms of modality, Chugai Pharmaceutical has shown particular interest in other, mab, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Chugai Pharmaceutical and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Chugai Pharmaceutical's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.